Novartis India Limited
Bombay Stock ExchangeTotal Valuation
Novartis India Limited carries a market capitalization of 36.02B, placing it among publicly traded companies globally. Its enterprise value stands at 25.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 36.02B |
| Enterprise Value | 25.96B |
Valuation Ratios
Novartis India Limited trades at a trailing price-to-earnings ratio of 25.26.
| PE Ratio | 25.26 |
| PS Ratio | 7.39 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Novartis India Limited trades at an EV/EBITDA multiple of 26.57 and an EV/FCF ratio of 4,700.05. The EV/Sales ratio of 7.39 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.57 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.39 |
| EV / EBITDA | 26.57 |
| EV / EBIT | 26.57 |
| EV / FCF | 4,700.05 |
Financial Position
Novartis India Limited maintains a current ratio of 10.21, meaning it holds 10.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.47, indicating moderate leverage, while an interest coverage ratio of 135.74 demonstrates strong ability to service its debt obligations.
| Current Ratio | 10.21 |
| Quick Ratio | 8.75 |
| Debt / Equity | 1.47 |
| Debt / EBITDA | N/A |
| Interest Coverage | 135.74 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 461.92 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Novartis India Limited has paid 311.80M in income taxes, reflecting an effective tax rate of 23.28.
| Income Tax | 311.80M |
| Effective Tax Rate | 23.28 |
Stock Price Statistics
Novartis India Limited's stock has gained approximately 40.40321% over the past 52 weeks. The 50-day moving average sits at 1,302.69, while the 200-day moving average is 973.17.
| Beta (5Y) | N/A |
| 52-Week Price Change | 40.40321% |
| 50-Day Moving Average | 1,302.69 |
| 200-Day Moving Average | 973.17 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Novartis India Limited generated 3.52B in revenue and converted that into 1.03B in net income, yielding earnings per share of 41.64. EBITDA reached 977.30M, while operating income came in at 977.30M.
| Revenue | 3.52B |
| Gross Profit | 1.56B |
| Operating Income | 977.30M |
| Pretax Income | 1.34B |
| Net Income | 1.03B |
| EBITDA | 977.30M |
| EBIT | 977.30M |
| Earnings Per Share (EPS) | 41.64 |
Margins
Novartis India Limited operates with a gross margin of 44.33, reflecting its pricing power and cost economics. The operating margin of 27.80 and net profit margin of 29.24 provide insight into operational efficiency.
| Gross Margin | 44.33 |
| Operating Margin | 27.80 |
| Pretax Margin | 38.11 |
| Profit Margin | 29.24 |
| EBITDA Margin | 27.80 |
Scores
Novartis India Limited posts an Altman Z-Score of 21.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 21.42 |